478698-84-9

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 114873-01-7 N-Boc-3-fluoro-L-phenylalanine 

Downstream Products

• 625110-43-2 [4-[1,3]dioxan-2-yl-(1S)-(3-fluorobenzyl)-2-oxo-butyl]carbamic acid tert-butyl ester 
• 625110-48-7 (5S)-tert-butoxycarbonylamino-6-(3-fluorophenyl)-4-oxohexanoic acid 3-hydroxypropyl ester 
• 625110-45-4 methanesulfonic acid (2S)-tert-butoxycarbonylamino-1-(2-[1,3]dioxan-2-yl-ethyl)-(3R)-(3-fluorophenyl)propyl ester 
• 848444-61-1 (S)-[1-(3-fluorobenzyl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Process research on [(2S)-(3-fluorophenyl)-(1S)-(5-oxotetrahydrofuran-2-yl) ethyl]carbamic acid tert-butyl ester, a lactone intermediate for an aspartyl protease inhibitor

Two processes for the preparation of lactone [2S-(3-fluorophenyl)-1S-(5- oxotetrahydrofuran-2-yl)ethyl]carbamic acid tert-butyl ester 1 starting from S-BOC-(3-fluorophenyl)alanine 3 are described. (S)-(3-Fluorophenyl)alanine N-methyl-N-methoxy amide 10, t

3-SUBSTITUTED 1,2,3-TRIAZIN-4-ONE'S AND 3-SUBSTITUTED 1,3-PYRIMIDINONE'S FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES

This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson''s disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as in disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin, or where the respiratory depression results form a medical condition such as central sleep apnea, stroke- induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi''s syndrome and drowning. In a particular aspect, the invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.

HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME AND THEIR PHARMACEUTICAL USES

This invention relates to a novel series of chemical compounds useful as Human immunodeficiency Virus (HIV) protease inhibitors and to the use of such compounds as antiviral agents. The invention further relates to pharmaceutical compositions containing s

METHODS FOR MANUFACTURE OF DIHYDRO-FURAN-2-ONE DERIVATIVES

This invention relates to dihydro-furan-2-one derivatives, their intermediates and methods of manufacture. As such, the present invention includes methods of making a compound of the formula (V-1), wherein R2 and p are herein defined. The prese